Dermata Therapeutics, Inc. DRMA
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Dermata Therapeutics, Inc. (DRMA) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -204%.
About Dermata Therapeutics
Dermata Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 1241% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$8M | -$12M | -$8M | -$10M | -$8M | -$3M |
| Free cash flow | — | — | — | — | -$6M | -$4M |
| EPS (diluted) | $-8.16 | $-80.32 | $-399.91 | $-139.20 | $-24.30 | $-16.90 |
| Net margin | — | — | — | — | — | — |
| ROIC | -98.7% | -633.2% | -100.0% | -126.9% | -61.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Dermata Therapeutics pay a dividend?
Not currently.
Is Dermata Therapeutics a good stock to buy?
We do not give buy or sell advice. Dermata Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.